Pfizer CEO and Other Drug Company Leaders Condemn Texas Abortion Pill Ruling

Senior executives of far more than 250 pharmaceutical and biotech companies on Monday issued a scorching condemnation of a ruling by a federal choose that invalidated the Food stuff and Drug Administration’s 23-calendar year-outdated approval of the abortion tablet mifepristone, and they called for the conclusion to be reversed.

“The choice ignores a long time of scientific proof and legal precedent,” said the letter, which was signed by leaders of some of the industry’s most outstanding companies, such as Albert Bourla, chief executive of Pfizer and Alisha Alaimo, president of Biogen.

The ruling, by Choose Matthew J. Kacsmaryk of the U.S. District Court docket for the Northern District of Texas, “has established a precedent for diminishing F.D.A.’s authority above drug approvals, and in so performing, produces uncertainty for the total biopharma industry,” the letter argues.

The letter also mentioned that pharmaceutical organizations depend on the F.D.A.’s autonomy to deliver solutions to market place underneath a “reliable regulatory system for drug analysis and approval.”

“If courts can overturn drug approvals without having regard for science or proof,” the letter reported, “or for the complexity demanded to totally vet the security and efficacy of new prescription drugs, any drugs is at chance for the identical outcome as mifepristone.”